EUCTR2012-003609-80-CZ进行中（未招募）1 期
European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits.
Ruprecht-Karls-University Heidelberg, Medical Faculty0 个研究点目标入组 264 人开始时间: 2013年7月12日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 264
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients presenting with acute ischemic Middle Cerebral Artery (MCA) stroke
- •- Patient, or legally acceptable representative has given written
- •informed consent. An independent witness may sign the consent form if the patient is able to give verbal consent, but unable to sign
- •- Patient’s age is =18 years
- •- Treatment onset within = 4.5 – 9 hours after stroke onset*†
- •*Patients with 'wake up' strokes may be included. 'Wake up' strokes are defined as having no stroke symptoms at sleep onset, but on waking.
- •The time of stroke onset is to be taken as the mid-point between sleep onset (or last known to be normal) and time of waking.
- •†Patients indicated for intravenous thrombolysis that arrives at clinic must be treated within 1 hour upon arrival in the hospital according to standard care. If standard treatment can be given within 4.5 hours after stroke onset, these patients can’t be included in the study.
- •- NIHSS score of 4 to 26 with clinical signs of hemispheric infarction
- •- Penumbral mismatch imaging via local assessment using a computer based analysis system (e.g. RAPID) if available, using a perfusion volume (PWI) to infarct core (DWI) ratio of = 1.2, and a minimum perfusion lesion volume of 20 ml
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 132
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 132
排除标准
- •-Patients indicated for arterial thrombolysis (with mechanical recanalization) who can be treated within 6 hours after stroke onset*
- •*patients that can receive standard treatment must be treated within 1 hour upon arrival in the hospital
- •- Intracranial hemorrhage (ICH) identified by CT or MRI
- •- Rapidly improving symptoms, particularly if, in the opinion of the investigator, the improvement is likely to result in the patient having an NIHSS score of <4 at randomization
- •- Pre-stroke mRS score of >1 (indicating previous disability)
- •- Contra indication to imaging with MRI
- •- Infarct core >1/3 MCA territory qualitatively or >100 ml quantitatively
- •(determined by DWI lesion on MRI)
- •- Any MRI findings indicative of a high risk of ICH related to potential ivrtPA treatment in the judgment of the investigator
- •- Participation in any investigational study in the previous 30 days
- •- A life expectancy of <3 months
- •- Any condition that, in the opinion of the investigator, could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study (this applies to patients with severe microangiopathy such as hemolytic uremic syndrome or
- •thrombotic thrombocytopenic purpura).
- •- Pregnant (clinically evident) or breastfeeding women
- •- Previous stroke within the three months prior to randomization
- •- Recent history (in the opinion of the investigator) or clinical
- •presentation of ICH, subarachnoid hemorrhage (SAH), arterio-venous (AV) malformation, aneurysm, or erebral neoplasm.
- •- Use of oral anticoagulants within 48 hours prior to randomization
- •(including, but not limited to Rivaroxaban, Apixaban, or Edoxaban) and a prolonged prothrombin time (INR > 1.6) or any activated partial thromboplastin (aPTT) time exceeding 1.5 times the normal range or prolonged Thrombin-Time (TT), indicating the potential use of Dabigatran-Etexilate.
- •- Use of heparin, except for low dose subcutaneous heparin, within 48 hours prior to randomization
- •- Use of glycoprotein IIb-IIIa inhibitors within 72 hours prior to randomization.
- •- Platelet count <100.000/µl (<100G/l)
- •- Blood glucose <50mg/dl (2.8 mmol/l) or >400mg/dl (22.2mmol/l)
- •- Uncontrolled hypertension defined by a blood pressure > 185 mmHg
- •systolic or >110 mmHg diastolic on at least 2 separate occasions at least 10 minutes apart, or requiring aggressive treatment to reduce the blood pressure to within these limits. The definition of aggressive treatment is left to the discretion of the investigator.
- •- Hereditary or acquired hemorrhagic diathesis
- •- Gastrointestinal or urinary bleeding within 21 days prior to
- •randomization
- •- Manifest or recent acute pancreatitis
- •- Manifest severe liver disease including hepatic failure, cirrhosis, portal hypertension and active hepatitis
- •- Major surgery within 14 days prior to randomization which poses a risk in the opinion of the investigator.
- •- Recent (within 10 days) traumatic external heart massage, obstetrical delivery, recent puncture of a non-compressible blood-vessel
- •- Exposure to a thrombolytic agent within 72 hours prior to
- •randomization
- •- Hypersensitivity to alteplase or any of the excipients
研究者
相似试验
进行中（未招募）
1 期
Extending the time for thrombolytic treatment after stroke.EUCTR2012-003609-80-DERuprecht-Karls-University Heidelberg, Medical Faculty264
进行中（未招募）
1 期
Extending the time for thrombolytic treatment after stroke.Acute Ischemic StrokeEUCTR2012-003609-80-GBRuprecht-Karls-University Heidelberg, Medical Faculty264
进行中（未招募）
1 期
Extending the time for thrombolytic treatment after stroke.Acute Ischemic StrokeEUCTR2012-003609-80-ITRuprecht-Karls-University Heidelberg, Medical Faculty264
进行中（未招募）
1 期
Extending the time for thrombolytic treatment after stroke.EUCTR2012-003609-80-ESRuprecht-Karls-University Heidelberg, Medical Faculty264
进行中（未招募）
1 期
Extending the time for thrombolytic treatment after stroke.EUCTR2012-003609-80-ATRuprecht-Karls-University Heidelberg, Medical Faculty264